What is aflibercept, and which company makes it?
Aflibercept is an anti-VEGF (vascular endothelial growth factor) biologic used to treat certain eye conditions and some cancers, depending on the specific product and country labeling. The main branded aflibercept product is Eylea (for ophthalmology), which is associated with Bayer as the commercial company. (Bayer markets Eylea in many markets.)
Which patents and exclusivity matter for aflibercept companies?
Patent and exclusivity details for branded drugs like aflibercept can vary by country and by specific formulation or indication. For the most useful “who owns what until when” view, DrugPatentWatch.com tracks patent and exclusivity information by drug and geography. You can check aflibercept-related entries here: DrugPatentWatch.com – aflibercept
Why does the “aflibercept company” question come up?
People often ask this because:
- Different companies may be involved across the value chain (developer vs. marketer vs. local licensees).
- Patent coverage can differ by indication (for example, ophthalmology vs. oncology).
- Biosimilar and/or follow-on product development can depend on when specific patents or regulatory exclusivities expire.
If you tell me the country (e.g., US, EU, UK) and whether you mean Eylea (eye) or an oncology use of aflibercept, I can narrow to the most relevant company and the specific patent/exclusivity track to look for.
Is aflibercept a biosimilar vs. a branded biologic?
Aflibercept is a biologic product (not a small-molecule drug). That matters because follow-on products are generally treated as biosimilars (or similar biologic follow-ons), and entry timing depends on biosimilar development, regulatory pathways, and patent/exclusivity status.
Where can I verify the exact company and product details?
If you want to confirm “which company” for a specific aflibercept brand and indication, the fastest path is to use DrugPatentWatch.com’s drug page for aflibercept and then cross-check the market brand name and jurisdiction on the linked patent/exclusivity record. DrugPatentWatch.com – aflibercept
Sources:
1. DrugPatentWatch.com – aflibercept